DEVELOPMENT AND OPTIMIZATION OF METHOTREXATE-LOADED GLYCEROSOMES USING BOX–BEHNKEN DESIGN FOR ENHANCED TOPICAL DRUG DELIVERY
Abstract
Methotrexate is an effective disease-modifying antirheumatic drug (DMARD) widely used in the management of rheumatoid arthritis and psoriasis; however, its conventional administration is associated with poor patient compliance and systemic adverse effects. The present study aimed to develop and optimize methotrexate-loaded glycerosomes for enhanced topical drug delivery using a Box–Behnken response surface design. The formulation was optimized by evaluating the effects of phosphatidylcholine, stearylamine, and cholesterol on entrapment efficiency and vesicle size. Thirteen experimental formulations were prepared and statistically analyzed using Design-Expert® software. Among all formulations, the optimized formulation (F7) exhibited a high entrapment efficiency of 89.85%, a small vesicle size of 160.74 nm, and a zeta potential of −39.65 mV, indicating excellent colloidal stability. The optimized glycerosomes demonstrated sustained in vitro drug release, achieving 98.78% cumulative drug release over 12 hours. Release kinetic analysis revealed that drug release predominantly followed the Higuchi diffusion model (R² = 0.9843), indicating diffusion-controlled release from the lipid matrix. The close agreement between predicted and experimental responses confirmed the validity and robustness of the optimization model. The optimized methotrexate-loaded glycerosomal formulation exhibited desirable physicochemical characteristics, prolonged drug release, and excellent stability, suggesting its potential as an effective topical drug delivery system for improving therapeutic efficacy while minimizing systemic side effects in the treatment of inflammatory skin disorders.